Loading…
Quality assurance of the EORTC trial 22911. A phase III study of post-operative external radiotherapy in pathological stage T3N0 prostatic carcinoma: the dummy run
Introduction: A dry run of a clinical trial (EORTC 22911) is presented in which 12 centres have participated. These are the centres which have contributed the largest number of patients to the trial. Material and methods: Each participating centre received data from a suitable patient. Investigators...
Saved in:
Published in: | Radiotherapy and oncology 2002-07, Vol.64 (1), p.65-73 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c276t-b2e64da03abad525add92425cce0ed261f8eabd4f89d64ab2899bc6d2cf2e3c13 |
---|---|
cites | cdi_FETCH-LOGICAL-c276t-b2e64da03abad525add92425cce0ed261f8eabd4f89d64ab2899bc6d2cf2e3c13 |
container_end_page | 73 |
container_issue | 1 |
container_start_page | 65 |
container_title | Radiotherapy and oncology |
container_volume | 64 |
creator | Davis, J.Bernard Reiner, Béatrice Dusserre, Andrée Giraud, Jean-Yves Bolla, Michel |
description | Introduction: A dry run of a clinical trial (EORTC 22911) is presented in which 12 centres have participated. These are the centres which have contributed the largest number of patients to the trial.
Material and methods: Each participating centre received data from a suitable patient. Investigators were asked to plan and ‘treat’ the patient according to the protocol guidelines and return the data for evaluation of compliance.
Results: The results show that compliance to the protocol guidelines was generally good. There were a few minor deviations in the dose and fractionation schedule, in the volume reduction for the booster dose and in the dose prescription point. None of these deviations will affect the outcome of the study. The most important observation is the large inter-centre variation in target volumes.
Conclusions: The results of this study underlines the need for a strict definition of the target volume and the adoption of the ICRU 50 recommendations in future protocols. |
doi_str_mv | 10.1016/S0167-8140(02)00143-3 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72055869</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0167814002001433</els_id><sourcerecordid>72055869</sourcerecordid><originalsourceid>FETCH-LOGICAL-c276t-b2e64da03abad525add92425cce0ed261f8eabd4f89d64ab2899bc6d2cf2e3c13</originalsourceid><addsrcrecordid>eNqFkc1u1DAUhS0EotPCI4C8QrBIsZ0_hw2qRi2MVFEBw9q6sW86Rkmc2k5FnocXxfMjWLKxF_7Ouef6EPKKs0vOePX-ezrqTPKCvWXiHWO8yLP8CVlxWTcZk7J-SlZ_kTNyHsJPxphgef2cnHEhmCzrekV-f52ht3GhEMLsYdRIXUfjDun13bftmkZvoadCNJxf0is67SAg3Ww2NMTZLHt2ciFmbkIP0T4ixV8R_Zg0Hox1ycjDtFA70gnizvXu3ur0GCLcI93mXxidfDJIWk01eG1HN8CHQwAzD8NC_Ty-IM866AO-PN0X5MfN9Xb9Obu9-7RZX91mWtRVzFqBVWGA5dCCKUUJxjSiEKXWyNCIincSoTVFJxtTFdAK2TStrozQncBc8_yCvDn6pkgPM4aoBhs09j2M6OagasHKUlZNAssjqFP24LFTk7cD-EVxpvbtqEM7av_1igl1aEflSff6NGBuBzT_VKc6EvDxCGBa89GiV0FbTKUY61FHZZz9z4g_sBmhPg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72055869</pqid></control><display><type>article</type><title>Quality assurance of the EORTC trial 22911. A phase III study of post-operative external radiotherapy in pathological stage T3N0 prostatic carcinoma: the dummy run</title><source>ScienceDirect Freedom Collection</source><creator>Davis, J.Bernard ; Reiner, Béatrice ; Dusserre, Andrée ; Giraud, Jean-Yves ; Bolla, Michel</creator><creatorcontrib>Davis, J.Bernard ; Reiner, Béatrice ; Dusserre, Andrée ; Giraud, Jean-Yves ; Bolla, Michel ; EORTC</creatorcontrib><description>Introduction: A dry run of a clinical trial (EORTC 22911) is presented in which 12 centres have participated. These are the centres which have contributed the largest number of patients to the trial.
Material and methods: Each participating centre received data from a suitable patient. Investigators were asked to plan and ‘treat’ the patient according to the protocol guidelines and return the data for evaluation of compliance.
Results: The results show that compliance to the protocol guidelines was generally good. There were a few minor deviations in the dose and fractionation schedule, in the volume reduction for the booster dose and in the dose prescription point. None of these deviations will affect the outcome of the study. The most important observation is the large inter-centre variation in target volumes.
Conclusions: The results of this study underlines the need for a strict definition of the target volume and the adoption of the ICRU 50 recommendations in future protocols.</description><identifier>ISSN: 0167-8140</identifier><identifier>EISSN: 1879-0887</identifier><identifier>DOI: 10.1016/S0167-8140(02)00143-3</identifier><identifier>PMID: 12208577</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Clinical trials ; Combined Modality Therapy ; Humans ; Male ; Multicenter Studies as Topic - standards ; Prostate cancer ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - radiotherapy ; Prostatic Neoplasms - surgery ; Protocol compliance ; Quality assurance ; Quality Control ; Radiotherapy Dosage ; Radiotherapy, High-Energy - standards</subject><ispartof>Radiotherapy and oncology, 2002-07, Vol.64 (1), p.65-73</ispartof><rights>2002 Elsevier Science Ireland Ltd</rights><rights>Copyright 2002 Elsevier Science Ireland Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c276t-b2e64da03abad525add92425cce0ed261f8eabd4f89d64ab2899bc6d2cf2e3c13</citedby><cites>FETCH-LOGICAL-c276t-b2e64da03abad525add92425cce0ed261f8eabd4f89d64ab2899bc6d2cf2e3c13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12208577$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Davis, J.Bernard</creatorcontrib><creatorcontrib>Reiner, Béatrice</creatorcontrib><creatorcontrib>Dusserre, Andrée</creatorcontrib><creatorcontrib>Giraud, Jean-Yves</creatorcontrib><creatorcontrib>Bolla, Michel</creatorcontrib><creatorcontrib>EORTC</creatorcontrib><title>Quality assurance of the EORTC trial 22911. A phase III study of post-operative external radiotherapy in pathological stage T3N0 prostatic carcinoma: the dummy run</title><title>Radiotherapy and oncology</title><addtitle>Radiother Oncol</addtitle><description>Introduction: A dry run of a clinical trial (EORTC 22911) is presented in which 12 centres have participated. These are the centres which have contributed the largest number of patients to the trial.
Material and methods: Each participating centre received data from a suitable patient. Investigators were asked to plan and ‘treat’ the patient according to the protocol guidelines and return the data for evaluation of compliance.
Results: The results show that compliance to the protocol guidelines was generally good. There were a few minor deviations in the dose and fractionation schedule, in the volume reduction for the booster dose and in the dose prescription point. None of these deviations will affect the outcome of the study. The most important observation is the large inter-centre variation in target volumes.
Conclusions: The results of this study underlines the need for a strict definition of the target volume and the adoption of the ICRU 50 recommendations in future protocols.</description><subject>Clinical trials</subject><subject>Combined Modality Therapy</subject><subject>Humans</subject><subject>Male</subject><subject>Multicenter Studies as Topic - standards</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - radiotherapy</subject><subject>Prostatic Neoplasms - surgery</subject><subject>Protocol compliance</subject><subject>Quality assurance</subject><subject>Quality Control</subject><subject>Radiotherapy Dosage</subject><subject>Radiotherapy, High-Energy - standards</subject><issn>0167-8140</issn><issn>1879-0887</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><recordid>eNqFkc1u1DAUhS0EotPCI4C8QrBIsZ0_hw2qRi2MVFEBw9q6sW86Rkmc2k5FnocXxfMjWLKxF_7Ouef6EPKKs0vOePX-ezrqTPKCvWXiHWO8yLP8CVlxWTcZk7J-SlZ_kTNyHsJPxphgef2cnHEhmCzrekV-f52ht3GhEMLsYdRIXUfjDun13bftmkZvoadCNJxf0is67SAg3Ww2NMTZLHt2ciFmbkIP0T4ixV8R_Zg0Hox1ycjDtFA70gnizvXu3ur0GCLcI93mXxidfDJIWk01eG1HN8CHQwAzD8NC_Ty-IM866AO-PN0X5MfN9Xb9Obu9-7RZX91mWtRVzFqBVWGA5dCCKUUJxjSiEKXWyNCIincSoTVFJxtTFdAK2TStrozQncBc8_yCvDn6pkgPM4aoBhs09j2M6OagasHKUlZNAssjqFP24LFTk7cD-EVxpvbtqEM7av_1igl1aEflSff6NGBuBzT_VKc6EvDxCGBa89GiV0FbTKUY61FHZZz9z4g_sBmhPg</recordid><startdate>200207</startdate><enddate>200207</enddate><creator>Davis, J.Bernard</creator><creator>Reiner, Béatrice</creator><creator>Dusserre, Andrée</creator><creator>Giraud, Jean-Yves</creator><creator>Bolla, Michel</creator><general>Elsevier Ireland Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200207</creationdate><title>Quality assurance of the EORTC trial 22911. A phase III study of post-operative external radiotherapy in pathological stage T3N0 prostatic carcinoma: the dummy run</title><author>Davis, J.Bernard ; Reiner, Béatrice ; Dusserre, Andrée ; Giraud, Jean-Yves ; Bolla, Michel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c276t-b2e64da03abad525add92425cce0ed261f8eabd4f89d64ab2899bc6d2cf2e3c13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Clinical trials</topic><topic>Combined Modality Therapy</topic><topic>Humans</topic><topic>Male</topic><topic>Multicenter Studies as Topic - standards</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - radiotherapy</topic><topic>Prostatic Neoplasms - surgery</topic><topic>Protocol compliance</topic><topic>Quality assurance</topic><topic>Quality Control</topic><topic>Radiotherapy Dosage</topic><topic>Radiotherapy, High-Energy - standards</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Davis, J.Bernard</creatorcontrib><creatorcontrib>Reiner, Béatrice</creatorcontrib><creatorcontrib>Dusserre, Andrée</creatorcontrib><creatorcontrib>Giraud, Jean-Yves</creatorcontrib><creatorcontrib>Bolla, Michel</creatorcontrib><creatorcontrib>EORTC</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Radiotherapy and oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Davis, J.Bernard</au><au>Reiner, Béatrice</au><au>Dusserre, Andrée</au><au>Giraud, Jean-Yves</au><au>Bolla, Michel</au><aucorp>EORTC</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Quality assurance of the EORTC trial 22911. A phase III study of post-operative external radiotherapy in pathological stage T3N0 prostatic carcinoma: the dummy run</atitle><jtitle>Radiotherapy and oncology</jtitle><addtitle>Radiother Oncol</addtitle><date>2002-07</date><risdate>2002</risdate><volume>64</volume><issue>1</issue><spage>65</spage><epage>73</epage><pages>65-73</pages><issn>0167-8140</issn><eissn>1879-0887</eissn><abstract>Introduction: A dry run of a clinical trial (EORTC 22911) is presented in which 12 centres have participated. These are the centres which have contributed the largest number of patients to the trial.
Material and methods: Each participating centre received data from a suitable patient. Investigators were asked to plan and ‘treat’ the patient according to the protocol guidelines and return the data for evaluation of compliance.
Results: The results show that compliance to the protocol guidelines was generally good. There were a few minor deviations in the dose and fractionation schedule, in the volume reduction for the booster dose and in the dose prescription point. None of these deviations will affect the outcome of the study. The most important observation is the large inter-centre variation in target volumes.
Conclusions: The results of this study underlines the need for a strict definition of the target volume and the adoption of the ICRU 50 recommendations in future protocols.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>12208577</pmid><doi>10.1016/S0167-8140(02)00143-3</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0167-8140 |
ispartof | Radiotherapy and oncology, 2002-07, Vol.64 (1), p.65-73 |
issn | 0167-8140 1879-0887 |
language | eng |
recordid | cdi_proquest_miscellaneous_72055869 |
source | ScienceDirect Freedom Collection |
subjects | Clinical trials Combined Modality Therapy Humans Male Multicenter Studies as Topic - standards Prostate cancer Prostatic Neoplasms - pathology Prostatic Neoplasms - radiotherapy Prostatic Neoplasms - surgery Protocol compliance Quality assurance Quality Control Radiotherapy Dosage Radiotherapy, High-Energy - standards |
title | Quality assurance of the EORTC trial 22911. A phase III study of post-operative external radiotherapy in pathological stage T3N0 prostatic carcinoma: the dummy run |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T12%3A15%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Quality%20assurance%20of%20the%20EORTC%20trial%2022911.%20A%20phase%20III%20study%20of%20post-operative%20external%20radiotherapy%20in%20pathological%20stage%20T3N0%20prostatic%20carcinoma:%20the%20dummy%20run&rft.jtitle=Radiotherapy%20and%20oncology&rft.au=Davis,%20J.Bernard&rft.aucorp=EORTC&rft.date=2002-07&rft.volume=64&rft.issue=1&rft.spage=65&rft.epage=73&rft.pages=65-73&rft.issn=0167-8140&rft.eissn=1879-0887&rft_id=info:doi/10.1016/S0167-8140(02)00143-3&rft_dat=%3Cproquest_cross%3E72055869%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c276t-b2e64da03abad525add92425cce0ed261f8eabd4f89d64ab2899bc6d2cf2e3c13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=72055869&rft_id=info:pmid/12208577&rfr_iscdi=true |